AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04241380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Solutions
Description: Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
Study NCT05027191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Description: The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
Study NCT05027191 — intervention group
Intervention type: DRUG
Intervention: Desflurane
Description: Desflurane
Study NCT05027191 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane
Study NCT04241380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No anticoagulant solutions
Description: They will receive non-coagulant or coagulant treatment according to clinical conditions.
Study NCT04241380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant management
Description: Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
Study NCT00685659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Outpatient Treatment
Description: 9 hours of group counseling per week for 2-3 months
Study NCT00685659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive telephone-based counseling
Description: In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
Study NCT00685659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive telephone-based counseling plus incentives
Description: In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
Study NCT04422210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
Study NCT04025918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vasopressor automated delivery system
Description: Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm.
Study NCT04025918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
Study NCT04025918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
Study NCT04025918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
Study NCT04025918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
Study NCT04025918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual vasopressor delivery system
Description: Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm.
Study NCT01694706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: faldaprevir
Description: medium dose of faldaprevir
Study NCT01694706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: medium dose of faldaprevir
Study NCT01342471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV commercial stepping
Description: Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention
Study NCT01342471 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-min walk
Description: Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention
Study NCT00349973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
Study NCT00349973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
Study NCT02471729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnligHTN™ Renal Denervation System
Description: The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
Study NCT03849924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Self-affirmation implementation intentions in the form of a questionnaire.
Study NCT02923232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accommodative contact lens
Description: Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
Study NCT00347646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: 27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
Study NCT01694706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: medium dose of omeprazole
Study NCT04422210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
Study NCT03599427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic lidocaine
Description: Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
Study NCT03599427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
Study NCT04734353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 5mg
Description: Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
Study NCT04734353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
Study NCT05958992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Participants will self-administer experimenter-provided e-cigarettes
Study NCT04422210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
Study NCT04422210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
Study NCT01827176 — intervention group
Intervention type: OTHER
Intervention: Recurrent Acute Rhinosinusitis
Description: Clinical Characteristic of Recurrent Acute Rhinosinusitis
Study NCT00574106 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength)
Study NCT03981120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser and Traditional Acupuncture
Description: Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
Study NCT02623101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy
Description: Non-invasive imaging of the lesion
Study NCT02623101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsy
Description: Obtaining a skin sample of the suspicious lesion under local anesthetics
Study NCT02623101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: Excision of the basal cell carcinoma lesion under local anesthetics
Study NCT02623101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Excision of the basal cell carcinoma lesion under local anesthetics
Study NCT03045549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital biofeedback system
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session
Study NCT03045549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional home-based rehabilitation
Description: Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application
Study NCT04237987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
Study NCT04237987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin and corticosteroid
Description: ciclosporin and corticosteroid
Study NCT04237987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclosporin and corticosteroid
Description: ciclosporin and corticosteroid
Study NCT04018534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Verbal/Written Education
Description: This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
Study NCT04018534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Assisted Education
Description: The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
Study NCT04018534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hands-on Training
Description: The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
Study NCT03652792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan (Zhaoke)
Description: Azilsartan 20mg tablets from Zhaoke
Study NCT03652792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan (Takeda)
Description: Azilva 20mg tablets from Takeda
Study NCT02382913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aP booster
Description: Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
Study NCT02382913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TdaP booster
Description: Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination.
Study NCT03292757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Fluorescent dye - indocyanine green
Study NCT03475641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade
Description: The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
Study NCT03475641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The current standard treatment
Description: Tumescent anesthesia.
Study NCT03475641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The current standard treatment
Description: Tumescent anesthesia.
Study NCT02464501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paclitaxel administration using the OPC
Study NCT01384344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observational
Description: Observation during a physical exercise
Study NCT01384344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observational
Description: Observation during a physical exercise
Study NCT00665119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: 0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
Study NCT00665119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: NaCl 0.9 %
Study NCT00857194 — intervention group
Intervention type: PROCEDURE
Intervention: 2 hour Oral Glucose Tolerance Test
Description: Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
Study NCT00857194 — intervention group
Intervention type: PROCEDURE
Intervention: Fat Meal Test
Description: A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
Study NCT02376452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2mg/m2 iv gtt, d1
Study NCT02376452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1
Study NCT02376452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1
Study NCT02376452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
Study NCT02376452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: 400mg/m2 iv gtt,d1
Study NCT04419636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: capsules, orally
Study NCT01319734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C supplementation 500mg
Study NCT01319734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: this group receiving glyburide 5 mg alone
Study NCT04965779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
Study NCT04965779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum nursing care
Description: Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
Study NCT04965779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum nursing care
Description: Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
Study NCT00934999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burch urethropexy
Description: Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
Study NCT02980029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
Study NCT02980029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00934999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic mid-urethral sling (TVT)
Description: Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
Study NCT03866616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Builders Parenting Class
Description: Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
Study NCT03866616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (Usual care)
Description: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics.